GILDGilead Sciences, Inc.

GILD Stock Price, Valuation & Chart | Gilead Sciences, Inc.

Compare

$149.61-0.31 (-0.21%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Drug Manufacturers - General GILD intrinsic value GILD calculated fair value vs price

Overview Financials Dividends Ratios

GILD Historical price chart

GILD Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization185.75B

PE Ratio-383.6

EPS-0.39

Trading Volume4.92M

Today's High/Low152.54/148.83

Dividend Yield2.15

52 Week High/Low157.29/108.46

Shares Outstanding1.24B

GILD Financial Statement

GILD Analyst ratings

GILD Analysis & performance metrics

GILD Company profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and…

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the…

GILD Management team

Name

Position

Deborah H. Telman J.D.

Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary

Jacquie Ross C.F.A.

Vice President of Investor Relations

Linda Slanec Higgins Ph.D.

Senior Vice President of Research, Innovation & Portfolio

Flavius Martin M.D.

Executive Vice President of Research

Daniel P. O'DayCEO

Chairman & Chief Executive Officer

Andrew D. DickinsonCFO

Chief Financial Officer

Johanna Mercier

Chief Commercial Officer

Diane E. Wilfong

Interim Corporate Controller, Chief Accounting Officer & Principal Accounting Officer

Name

Position

Deborah H. Telman J.D.

Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary

Jacquie Ross C.F.A.

Vice President of Investor Relations

Linda Slanec Higgins Ph.D.

Senior Vice President of Research, Innovation & Portfolio

Flavius Martin M.D.

Executive Vice President of Research

Daniel P. O'DayCEO

Chairman & Chief Executive Officer

Andrew D. DickinsonCFO

Chief Financial Officer

Johanna Mercier

Chief Commercial Officer

Diane E. Wilfong

Interim Corporate Controller, Chief Accounting Officer & Principal Accounting Officer

Management Team

Deborah H. Telman J.D.

Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary

Jacquie Ross C.F.A.

Vice President of Investor Relations

Linda Slanec Higgins Ph.D.

Senior Vice President of Research, Innovation & Portfolio

Flavius Martin M.D.

Executive Vice President of Research

Daniel P. O'DayCEO

Chairman & Chief Executive Officer

Andrew D. DickinsonCFO

Chief Financial Officer

Johanna Mercier

Chief Commercial Officer

Diane E. Wilfong

Interim Corporate Controller, Chief Accounting Officer & Principal Accounting Officer

Management

Deborah H. Telman J.D.

Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary

Jacquie Ross C.F.A.

Vice President of Investor Relations

Linda Slanec Higgins Ph.D.

Senior Vice President of Research, Innovation & Portfolio

Flavius Martin M.D.

Executive Vice President of Research

Daniel P. O'DayCEO

Chairman & Chief Executive Officer

Andrew D. DickinsonCFO

Chief Financial Officer

Johanna Mercier

Chief Commercial Officer

Diane E. Wilfong

Interim Corporate Controller, Chief Accounting Officer & Principal Accounting Officer

Total 8 executives

GILD Frequently asked questions

What is Gilead Sciences, Inc. (GILD) Stock Price?

Current stock price of Gilead Sciences, Inc. (GILD) stock is $149.61. The stock price is -0.21% lower in the session. The intraday range can be seen from this page. Volume of Gilead Sciences, Inc. (GILD) stock is 4.92M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Gilead Sciences, Inc. (GILD) stock price going up or down today?

The stock price of Gilead Sciences, Inc. (GILD) can change with earnings, company news, and overall market sentiment. Gilead Sciences, Inc. operates in the Healthcare / Drug Manufacturers - General market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Gilead Sciences, Inc. stock expensive at its current price?

Whether Gilead Sciences, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for GILD on this page is -383.62. EPS on this page is -0.39. Compare those figures with peers and growth expectations before deciding if the current Gilead Sciences, Inc. price is justified.

How has the stock price of Gilead Sciences, Inc. (GILD) performed historically?

Historical performance for Gilead Sciences, Inc. (GILD) is shown on the price chart on this page. Review multi-period moves alongside volume to see how GILD reacted to past earnings and market events.

Should I buy Gilead Sciences, Inc. (GILD) stock, at this price?

Buying Gilead Sciences, Inc. (GILD) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.